MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
(a)
On September14, 2017, Eric Topol, M.D. delivered his resignation from the board of directors (the “Board”) of MyoKardia, Inc., as Delaware corporation (the “Company”), including all committees of the Board on which he served, effective on September14, 2017. Dr.Topol was a member of the Science and Technology Committee of the Board at the time of his resignation. Dr.Topol’s resignation was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. Dr.Topol will continue to serve as an advisor to the Company.
About MYOKARDIA,INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.
